Eyepoint Pharmaceuticals (NASDAQ:EYPT) Announces Earnings Results

Eyepoint Pharmaceuticals (NASDAQ:EYPT) announced its earnings results on Wednesday. The company reported ($0.99) EPS for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.20), FiscalAI reports. Eyepoint Pharmaceuticals had a negative net margin of 739.39% and a negative return on equity of 88.31%. The firm had revenue of $0.70 million for the quarter, compared to analyst estimates of $0.35 million.

Here are the key takeaways from Eyepoint Pharmaceuticals’ conference call:

• Phase III wet AMD readouts (LUGANO mid-year, LUCIA shortly after) are expected soon and management says two consecutive positive IDMC reviews support DURAVYU’s safety profile, which could be a near-term catalyst if top-line results are favorable.
• Phase III DME programs (COMO and CAPRI) are enrolling rapidly, with management targeting full enrollment in both pivotal trials in Q3 2026 and top-line data in H2 2027, driven by strong investigator and patient interest.
• Commercial and CMC readiness progressed—Northbridge cGMP facility is online, pre-approval inspection preparations underway, and the company added a Chief Commercial Officer as it builds launch capabilities for DURAVYU.
• Financials show pressure—Q1 revenue fell to $0.7M (from $24.5M a year earlier) due to prior deferred revenue recognition, operating expenses rose to $88M, and net loss was $85M; cash is $223M (down from $306M) though management expects runway into Q4 2027.

Eyepoint Pharmaceuticals Price Performance

Shares of NASDAQ:EYPT traded down $0.40 during midday trading on Wednesday, hitting $13.35. The company had a trading volume of 1,214,757 shares, compared to its average volume of 856,506. Eyepoint Pharmaceuticals has a twelve month low of $5.30 and a twelve month high of $19.11. The stock has a market cap of $1.12 billion, a price-to-earnings ratio of -4.22 and a beta of 1.76. The business’s 50-day simple moving average is $14.40 and its 200-day simple moving average is $14.60.

Analyst Upgrades and Downgrades

A number of brokerages have commented on EYPT. Chardan Capital increased their target price on Eyepoint Pharmaceuticals from $27.00 to $29.00 and gave the company a “buy” rating in a report on Wednesday, March 4th. HC Wainwright increased their target price on Eyepoint Pharmaceuticals from $23.00 to $30.00 and gave the company a “buy” rating in a report on Thursday, March 5th. Citigroup increased their target price on Eyepoint Pharmaceuticals from $31.00 to $35.00 and gave the company a “buy” rating in a report on Monday, March 9th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a report on Tuesday, April 21st. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $32.20.

Insider Activity at Eyepoint Pharmaceuticals

In related news, insider Ramiro Ribeiro sold 2,437 shares of the stock in a transaction that occurred on Friday, April 17th. The stock was sold at an average price of $15.00, for a total value of $36,555.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 4.46% of the company’s stock.

Institutional Investors Weigh In On Eyepoint Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in EYPT. Invesco Ltd. grew its position in Eyepoint Pharmaceuticals by 16.6% in the fourth quarter. Invesco Ltd. now owns 339,004 shares of the company’s stock worth $6,194,000 after acquiring an additional 48,186 shares during the period. Virtus Investment Advisers LLC grew its position in Eyepoint Pharmaceuticals by 29.5% in the fourth quarter. Virtus Investment Advisers LLC now owns 16,638 shares of the company’s stock worth $304,000 after acquiring an additional 3,795 shares during the period. Susquehanna Portfolio Strategies LLC grew its position in Eyepoint Pharmaceuticals by 22.5% in the fourth quarter. Susquehanna Portfolio Strategies LLC now owns 74,944 shares of the company’s stock worth $1,369,000 after acquiring an additional 13,750 shares during the period. Suvretta Capital Management LLC grew its position in Eyepoint Pharmaceuticals by 26.4% in the fourth quarter. Suvretta Capital Management LLC now owns 7,827,685 shares of the company’s stock worth $143,012,000 after acquiring an additional 1,634,970 shares during the period. Finally, Orbimed Advisors LLC grew its position in Eyepoint Pharmaceuticals by 37.4% in the fourth quarter. Orbimed Advisors LLC now owns 2,468,314 shares of the company’s stock worth $45,096,000 after acquiring an additional 672,314 shares during the period. Institutional investors and hedge funds own 99.41% of the company’s stock.

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.